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Abstract
Some controversy exists on the specific genetic variants that are associated with nicotine dependence and smoking-related
phenotypes. The purpose of this study was to analyse the association of smoking status and smoking-related phenotypes
(included nicotine dependence) with 17 candidate genetic variants: CYP2A6*162, CYP2A6*2 (1799T.A) [rs1801272],
CYP2A6*9 (248T.G) [rs28399433], CYP2A6*12, CYP2A13*2 (3375C.T) [rs8192789], CYP2A13*3 (7520C.G), CYP2A13*4
(579G.A), CYP2A13*7 (578C.T) [rs72552266], CYP2B6*4 (785A.G), CYP2B6*9 (516G.T), CHRNA3 546C.T [rs578776],
CHRNA5 1192G.A [rs16969968], CNR1 3764C.G [rs6928499], DRD2-ANKK1 2137G.A( Taq1A) [rs1800497], 5HTT LPR, HTR2A
21438A.G [rs6311] and OPRM1 118A.G [rs1799971]. We studied the genotypes of the aforementioned polymorphisms in
a cohort of Spanish smokers (cases, N=126) and ethnically matched never smokers (controls, N=80). The results showed
significant between-group differences for CYP2A6*2 and CYP2A6*12 (both P,0.001). Compared with carriers of variant
alleles, the odds ratio (OR) for being a non-smoker in individuals with the wild-type genotype of CYP2A6*12 and DRD2-
ANKK1 2137G.A( Taq1A) polymorphisms was 3.60 (95%CI: 1.75, 7.44) and 2.63 (95%CI: 1.41, 4.89) respectively. Compared
with the wild-type genotype, the OR for being a non-smoker in carriers of the minor CYP2A6*2 allele was 1.80 (95%CI: 1.24,
2.65). We found a significant genotype effect (all P#0.017) for the following smoking-related phenotypes: (i) cigarettes
smoked per day and CYP2A13*3; (ii) pack years smoked and CYP2A6*2, CYP2A6*162, CYP2A13*7, CYP2B6*4 and DRD2-ANKK1
2137G.A( Taq1A); (iii) nicotine dependence (assessed with the Fagestrom test) and CYP2A6*9. Overall, our results suggest
that genetic variants potentially involved in nicotine metabolization (mainly, CYP2A6 polymorphisms) are those showing the
strongest association with smoking-related phenotypes, as opposed to genetic variants influencing the brain effects of
nicotine, e.g., through nicotinic acetylcholine (CHRNA5), serotoninergic (HTR2A), opioid (OPRM1) or cannabinoid receptors
(CNR1).
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Introduction
Cigarette smoking is the single most preventable cause of lung
cancer and a main source of morbimortality worldwide [1].
Smoking quit rates are low (,10% after 6 months) [2] and do not
increase substantially with pharmacological treatment [2,3].
Further, long-term (i.e. years) abstinence following treatment is
rare. Nicotine dependence is a main factor contributing to
maintaining the harmful cigarette smoking behavior [4,5]. Thus,
to indentify the main causes of nicotine dependence and smoking-
related phenotypes is of medical interest.
Evidence from classic studies on twins [6-10] and more recent
molecular approaches including wide genome linkage studies [11–
17] indicate that smoking-related phenotypes, particularly nicotine
dependence are highly heritable (for a review, see [18,19]). More
controversy exists on the specific genetic variants that have a
functional significance on such phenotypes, with a strong rationale
existing forpolymorphisms ingenesencodingnicotine-metabolizing
enzymes in the liver [cytochrome P450 2A6 (CYP2A6)a n dB 6
(CYP2B6)] and lungs (CYP2A13) [18]. Other candidate polymorphisms
are in genes encoding neuronal nicotinic acetylcholine receptors
(CHRNA3 and CHRN5), or in genes involved in dopaminergic,
serotoninergic,cannabinoidandopioidpathwaysrelatedtonicotine
reward and dependence, such as dopamine D2 receptor/ankyrin
repeat and kinase domain containing 1 (DRD2/ANKK1 dopamine
D2), serotoninergic transporter [5-HTT, also termed solute carrier
family 6, member 4 (SLC6A4)] and receptor (HTR2A), cannabinoid
receptor 1 (CNR1) and mu opioid receptor (OPRM1) [18].
The purpose of this study was to assess the association of
smoking status and smoking-related phenotypes (included nicotine
dependence) with 17 candidate genetic variants: CYP2A6*162,
CYP2A6*2 (1799T.A) [rs1801272], CYP2A6*9 (-48T.G)
[rs28399433], CYP2A6*12, CYP2A13*2 (3375C.T) [rs8192789],
CYP2A13*3 (7520C.G), CYP2A13*4 (579G.A), CYP2A13*7
(578C.T) [rs72552266] , CYP2B6*4 (785A.G), CYP2B6*9
(516G.T), CHRNA3 546C.T [rs578776], CHRNA5 1192G.A
[rs16969968], CNR1 3764C.G [rs6928499], DRD2-ANKK1
2137G.A( Taq1A) [rs1800497], 5HTT LPR, HTR2A -1438A
.G [rs6311] and OPRM1 118A.G [rs1799971]. We studied the
genotypes of the aforementioned polymorphisms in a cohort of
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(controls).
Materials and Methods
Participants
Written consent was obtained from each participant. The study
protocol was approved by the institutional ethics committee
(Universidad Europea de Madrid (UEM). Spain) and was in accordance
with the Declaration of Helsinki for Human Research of 1974 (last
modified in 2000).
A total of 206 individuals [all unrelated to each other and of the
same Caucasian (Spanish) descent for 3 or more generations]
enrolled in the study, including 126 smokers (cases, 64 male 62
female, mean age 54614 years, range 20–84) and 80 never-
smokers (controls, 37 male 43 female, mean age 42611 years, range
24–66). In the smokers’ group, 56 people were unhealthy smokers
(diagnosed with lung cancer) and 70 were healthy at the time of
the study. All cases met the following three criteria: 1) smoked
more tan 10 cigarettes per day at the time of the study, 2) had a
smoking history of more than 10 packs per year and 3) had more
than 3 scores in the Fagerstrom Test for Nicotine Dependence (see
below). Participants in the control group were life-time never
smokers who had taken at least one puff from a cigarette in their
life-time without developing a pattern of regular smoking.
Phenotype assessment
Nicotine dependence was assessed with the Fagerstrom Test for
Nicotine Dependence (FTND) [20]. The FTND is a six-item
questionnaire (score range 0–10) that is widely used to evaluate the
severity of nicotine dependence. Regular smokers were divided in
low-dependence (0–3 scores), medium-dependence (4–6 scores)
and high-dependence smokers (7–10 scores) according to this
scale.
Exposure to tobacco smoke (tobacco consumption) was assessed
as self-reported cigarettes per day (CPD) in the last year and pack
years smoked (PYS). The PYS is used to describe the number of
cigarettes a person has smoked over a lifetime, e.g. 1 PYS is
defined as 20 manufactured cigarettes (one pack) smoked per day
for one year.
Genotype assessment
During 2006–2009, we extracted blood leukocyte DNA from
the participants using a standard phenol chloroform protocol and
performed genotype analyses in the genetics laboratory of the
Universidad Europea de Madrid (Spain). Our study followed recent
recommendations for replicating genotype-phenotype association
studies [21]: genotyping was performed specifically for research
purposes, and the researchers in charge of genotyping were totally
blinded to the participants’ identities (blood samples were tracked
solely with bar-coding and personal identities were only made
available to the main study researcher who was not involved in
actual genotyping).
All genotyping was conducted by polymerase chain reaction
(PCR). Allele-specific PCR methods were applied for the detection
of 5-HTT LPR. The PCR products were then analyzed directly by
1.2% agarose gel electrophoresis. Genotyping of CYP2A6*12 and
CYP2A6*162 was performed by a nested PCR method according
to previously described protocols [22,23]. The genotypes of
CYP2A13*2 [rs8192789], CYP2A13*3, CHRNA5 1192G.A
[rs16969968] and HTR2A -1438A.G [rs6311] were analyzed
by PCR followed by Restriction Fragment Length Polymorphisms
(RFLPs); the PCR products were digested with HhaI, MspI, Taq
aI
and MspI respectively (New England Biolabs, Inc., Beverly, MA).
For all PCR-RFLP assays, the digested amplicons were separated
on a 1.5% agarose ethidium bromide-stained gel. Genotyping of
CYP2A6*2 [rs1801272], CYP2A6*9 [rs28399433], CYP2A13 579G
.A, CYP2A13 578C.T [rs72552266], CYP2B6*4 785A.G,
CYP2B6*9 516G.T and CHRNA3 546C.T [rs578776] were
performed with the single-base extension (SBE) system (ABI Prism
SNaPshot Multiplex Kit, Applied Biosystems, Foster City, CA).
For OPRM1 118A.G [rs1799971] and DRD2-ANKK1 2137G
.A( Taq1A) [rs1800497] genotyping we used real-time PCR
followed by melting curve analysis with fluorescence resonance
energy transfer (FRET) probes with a thermal cycler (Light Cycler
2.0 IVD, Roche Diagnostics, Barcelona, Spain). Real-time PCR
and Taqman probes were used to asses CNR1 3764C.G
[rs6928499] with a Step One Real-Time PCR System (Applied
Biosystems, Foster City, CA).
Statistical analysis
The chi-squared (x2) test was used to assess deviations of
genotype distribution from the Hardy-Weinberg equilibrium
(HWE) in the whole study sample (cases+controls), and in the
control group. We also compared mean values of smoking
phenotypes (years smoking, CPD, FTND, PYS) between genders
using the Student’s unpaired t test. The level of significance was set
at 0.05 for the two aforementioned analyses.
To compare smokers vs. non-smokers (case:control study), we used:
(i) the x
2 test for between-group comparisons of genotype
frequencies, and (ii) logistic regression to calculate the odds ratio
(OR) of being a non-smoker based on the studied polymorphisms.
Between-group comparisons of genotype frequencies were cor-
rected for multiple comparisons using the Bonferroni method, in
which the threshold P-value is obtained by dividing 0.05 by the
number of comparisons, i.e. n=17, corresponding to the 17
polymorphisms we studied (thus, threshold P-value=0.003).
To assess genotype associations with smoking-related pheno-
types within the smokers’ group (cohort study), we used the ANOVA
test to compare mean values of nicotine dependence (assessed with
the FTND), CPD and PYS among the different genotypes of each
polymorphism. The threshold P-value was obtained by dividing
0.05 by the number of comparisons for each polymorphism, i.e.
n=3, corresponding to each genotype (thus, threshold P-
value=0.017).
All statistical analyses were performed with the PASW/SPSS
Statistics 18.0 (SPSS Inc, Chicago, IL).
Results
Smoking phenotypes in cases (smokers)
The main values of smoking-related phenotypes in the smokers’
group are shown in Table 1. Participants in this group showed a
strong nicotine dependence and high levels of tobacco consump-
tion; 66% of the total group were heavy smokers (CPD$1 pack/
day) and 60% had medium-high nicotine dependence ($4 scores
in the FTND). Women (46611 years) tended to be younger than
men (61612 years) (P=0.129); as such, they had been smoking for
fewer years, and had lower values of CPD and PYS than men (all
P,0.001). The FTND score was similar in both genders (P=0.48).
Case-control study: Genotype comparisons between the
two study groups
Genotype success in the whole study sample was 99.88%, with
no failures observed in the smokers’ group. All genotype
distributions were in HWE in the whole study sample (case-
s+controls) except for CYP2A6*2 (P=0.001), CHRNA3 546C.T
(P=0.013), OPRM1 118A.G( P=0.02) and DRD2-ANKK1
Smoking Genes
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distributions were in HWE except for CYP2A6*2 (P=0.02), 5-
HTT LPR (P=0.007) and DRD2-ANKK1 2137G.A( Taq1A)
(P=0.02).
No between-gender differences were found for the whole study
sample, except for CYP2A6*162 and DRD2-ANKK1 2137G.A
(data not shown).
Genotype frequency distributions in the two study groups are
shown in Table 2. We found P-values below 0.05 for between-group
comparisons in CYP2A6*2, CYP2A6*12, CYP2A6*1x2, CYP2A13*2,
CHRNA3 546C.T, DRD2-ANKK1 2137G.A( Taq1A)a n d5-HTT
LPR; yet, after adjustment for multiple comparisons statistical
significance remained only for CYP2A6*2 and CYP2A6*12 (both
P,0.001, and thus below thethreshold P-valueof0.003). Compared
with carriers of variant alleles, the OR for being a non-smoker in
individuals with the wild-type genotype of CYP2A6*12 and DRD2-
ANKK1 2137G.A( Taq1A) polymorphisms was 3.60 (95%CI: 1.75,
7.44) and 2.63 (95%CI: 1.41, 4.89) respectively. Compared with the
wild-type genotype, the OR for being a non-smoker incarriers of the
minor CYP2A6*2 allele was 1.80 (95%CI: 1.24, 2.65). No other
significant association was found.
Cohort study: Association between genetic
polymorphism and smoking-related phenotypes within
the smokers’ group
After adjusting for multiple comparisons, the results of the
ANOVA test showed a significant genotype effect for the following
smoking-related phenotypes (Table 3, all P,0.017) (i) mean CPD
Table 1. Main characteristics of the smokers’ group.
Smoking phenotypes Men Women Total (men+women)
P for between-gender
comparison
Years smoking 40.2612.9 27.16 8.4 33.7612.7 ,0.001
CPD 30.7610.4 21.86 8.1 26.5610.0 ,0.001
PYS 53.0626.2 26.4610.3 39.9624.0 ,0.001
FTND 5.762.2 6.062.0 5.862.1 0.48
Abbreviations: CPD, cigarettes per day; FTND, Fargestrom Test for Nicotine Dependence; PYS, pack years smoked (describes the number of cigarettes a person has
smoked over long periods of time, e.g. 1 PYS=20 cigarettes (one pack) smoked per day for one year). Significant P-values for between-gender comparisons are shown in
bold.
Data are mean6SD.
doi:10.1371/journal.pone.0026668.t001
Table 2. Genotype frequency distributions (%) in the two study group, i.e. controls (non-smokers) and cases (smokers).
Non-
smokers Smokers
P-value for between-
group comparison
M/M M/m m/m M/M M/m m/m
CYP2A6*2 58.8 27.5 13.7 87.2 12.0 0.8 ,0.001
CYP2A6*9 89.70 10.3 0.0 87.1 11.3 1.6 0.389
CYP2A6*12 75.0 25.0 0.0 45.4 42.0 12.6 ,0.001
CYP2A6*162 81.3 18.8
a - 65.1 34.9
a - 0.027
CYP2A13*2 87.5 12.5 0.0 96.7 3.3 0.0 0.017
CYP2A13*3 82.2 15.1 2.7 77.3 22.7 0.0 0.268
CYP2A13*4 98.5 1.5 0.0 97.5 2.5 0.0 0.548
CYP2A13*7 100.0 0.0 0.0 99.2 0.8 0.0 0.652
CYP2B6*4 70.0 25.0 5.0 61.5 25.6 12.8 0.132
CYP2B6*9 50.0 36.0 14.0 56.4 33.3 10.3 0.568
CHRNA3 546C.T 70.4 26.8 2.8 56.7 43.3 0.0 0.018
CHRNA5 1192G.A 32.3 47.7 20.0 34.4 53.8 11.8 0.316
5-HTT LPR 40.9 35.2 23.9 24.0 52.0 24.0 0.029
HTR2A -1438A.G 26.8 52.1 21.1 32.8 41.6 25.6 0.364
OPRM1 118A.G 74.0 24.6 1.4 67.5 24.7 7.8 0.143
DRD2-ANKK1 2137G.A( Taq1A) 66.7 22.7 10.6 43.2 42.4 14.4 0.007
CNR1 3764C.G 68.5 26.0 5.5 67.5 31.0 1.6 0.257
Abbreviations:
aM, major allele; m, minor allele.
Symbol:
a frequency for M/m or m/m. See text for gene abbreviations. Between-group comparisons of genotype frequencies were corrected for multiple comparisons
using the Bonferroni method, in which the threshold P-value is obtained by dividing 0.05 by the number of comparisons, i.e. n=17, corresponding to the 17
polymorphisms we studied (thus, threshold P-value=0.003). P-values below the threshold P-value are shown in bold.
doi:10.1371/journal.pone.0026668.t002
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CYP2A13*7, CYP2B6*4 and DRD2-ANKK1 2137G.A( Taq1A);
(iii) nicotine dependence (FTND) and CYP2A6*9.
Discussion
Overall, our results suggest that genetic variants that can
influence nicotine metabolization (mainly, CYP2A6 polymor-
phisms) are those showing the strongest association with smoking
status and smoking-related phenotypes. No significant association
was observed for those genetic polymorphisms that are involved in
the brain effects of nicotine through nicotinic acetylcholine
(CHRNA3, CHRNA5), serotoninergic (HTR2A), opioid (OPRM1)
or cannabinoid receptors (CNR1) and serotonin transporters
(5HTT). The only candidate polymorphism involved in the brain
effects of nicotine that was associated with smoking status and with
tobacco consumption (expressed as PYS) was DRD2-ANKK1
2137G.A( Taq1A).
The strongest genetic association we found in our study with
smoking status and smoking-related phenotypes was for polymor-
phisms in CYP2A6, the gene encoding the principle nicotine C-
oxidase [24]. Smokers who are partially or totally deficient in this
enzyme owing to carriage of the variant allele of some CYP2A6
polymorphisms are ‘poor’ (or ‘slow’) nicotine metabolizers; as
such, they are theoretically expected to have a reduced need for
cigarette consumption compared with the wild-type genotype
[25,26] However, it is also possible that prolonged high levels of
brain nicotine owing to reduced metabolization might increase the
risk for nicotine dependence, leading to a certain ‘nicotine
tolerance’ phenomenon [27,28]. With regards to these consider-
ations, it must be kept in mind that the decrease in enzyme activity
is considerably more marked with carriage of the CYP2A6*2 allele
than with the CYP2A6*12 variant. Thus, *2 allele-carriers, who are
‘null-slow’ rather than ‘intermediate metabolizers’ could experi-
ence a phenomenon of ‘nicotine tolerance’ with high cigarette
consumption (.20 CPD) early in their smoking lifetime [27]. In
other words, smokers with the CYP2A6*2 allele might experiment
more negative effects when they start to become smokers; but
when they continue smoking they may experience prolonged
nicotine levels in the brain, thereby becoming more rapidly
tolerant and thus needing to smoke more [29]. Our findings are
consistent with the aforementioned biological implications of
CYP2A6*12 and CYP2A6*2 variants. First, both CYP2A6*2 and
CYP2A6*12 polymorphisms were strongly associated with smoking
status, yet the variant *2 and *12 alleles were underrepresented
and overrepresented respectively in smokers. Second, the
CYP2A6*2 variation, but not the CYP2A6*12 polymorphism was
associated with smoking phenotypes within the smokers’ group,
with those individuals homozygous for the *2 allele showing the
highest levels of long-term cigarette consumption (PYS). On the
other hand, carriage of the CYP2A6*162 duplication allele,
leading to faster nicotine metabolization was also associated with
higher PYS. Our results are in overall agreement with those
reported by Rao et al, who showed that individuals with the
duplication allele CYP2A6*162 had higher nicotine consumption
[23].
Regarding those genes involved in the central effects of nicotine,
we only found a significant association for DRD2-ANKK1 (Taq1A).
The variant A1 allele: (i) was associated with an increased chance
of being a non-smoker, (ii) tended to be overrepresented in non-
smokers compared with smokers (yet the between-group compar-
ison did not withstand statistical correction for multiple compar-
isons), and (iii) positively associated with PYS in smokers. There is
controversy in the literature: previous studies suggested and
association of the A1 allele with susceptibility to smoking [30] but
more recent studied failed to replicate such association. The
DRD2-ANKK1 gene is involved in the nicotine effects through
dopaminergic pathways, with the variant A1 allele being
associated with lower density of dopaminergic receptors (DRD2)
in the striatum [30–32]. Our findings might indeed suggest that
people with a functional deficit in the dopamine reward pathway
do not experience a reward with smoking initiation, which might
confer a protective role to the A1 allele against smoking initiation.
However, once they have become smokers, A1-carriers might
need to consume more nicotine to enhance the dopaminergic
system [30,33]. This might explain why the A1 allele was positively
associated with PYS in our smokers’ group.
A novelty of our study stems from the fact that we analyzed the
association of the HTR2A-1438A.G polymorphism with smoking
status and all smoking-related phenotypes, including nicotine
dependence. The serotoninergic system could theoretically be
implicated in habitual smoking because nicotine increases brain
serotonin secretion and nicotine withdrawal has the opposite effect
[34,35]. Polina et al found a higher frequency of the variant A
allele in European-derived Brazilian smokers than in their non-
smoking controls [35]. However, our results do not provide
evidence for an association between HTR2A -1438A.G and
smoking status. Reasons for disparity between the findings
reported by Polina et al and the present ones might lie, at least
partly, in the different ethnic background of the two study cohorts.
Notably, the frequency of the A allele was considerably lower in
their non-smoking controls (40%) compared with ours (53.6%).
On the other hand, we found no association for those genetic
polymorphisms that are involved in the brain effects of nicotine
through nicotinic acetylcholine (CHRNA3, CHRNA5), serotonin-
ergic (HTR2A), opioid (OPRM1), cannabinoid receptors (CNR1)o r
serotonin transporters (5HTT). Some studies reported a significant
association between the aforementioned variants and nicotine
dependence [35–39] while others failed to corroborate such
association [40–43]. A marked racial/ethnic diversity exists in
smoking behavior and smoking-related phenotypes (such as age of
smoking initiation, smoking rate or level of dependence), as well as
in the genotype frequencies of the functional polymorphisms we
studied here [44,45], which could explain, at least partly,
differences between studies.
We believe there are several novelties and strengths in our
design. This the first association study in the field that takes into
account the most important polymorphisms that are strong
candidates to influence smoking behavior, i.e. those involved in
nicotine metabolization, as well as in the brain effects of nicotine.
The results of our study are overall valid, as all the following
criteria were met [46]: the studied phenotypes (smoking status and
smoking-related phenotypes) were properly defined and accurately
recorded by a researcher who was blind to the genetic infor-
mation; both groups (smokers and non-smokers) were ethnically
matched; genotype assessment was unbiased and accurate; we
adjusted all statistical inferences for multiple comparisons; and the
results are overall consistent with previous research in the field
[45,47]. A weakness of our study was the low sample size of both
cohorts, yet we believe this can be partly overcome by the fact that
both cohorts were homogeneous and well defined in terms of
phenotype assessment.
In conclusion, our results suggest that genetic variants
potentially involved in nicotine metabolization (mainly, CYP2A6
polymorphisms) are those showing the strongest association with
smoking status and smoking-related phenotypes, as opposed to
most genetic variants that can influence the brain effects of
nicotine, except for the DRD2-ANKK1 2137G.A polymorphism.
Smoking Genes
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26668We believe studies as the present ones might help understanding
the role of genetics in smoking behavior and on potential smoking
cessation, and to better focus therapeutic approaches based on the
knowledge of each individual’s genetic predisposition to smoking.
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